Skip to main content
Clinical Trials/NCT01309061
NCT01309061
Completed
Not Applicable

Preliminary Investigation of the Effect of Human Adipose Tissue-derived Mesenchymal Stem Cell in Progressive Hemifacial Atrophy(Romberg's Disease)

R-Bio1 site in 1 country5 target enrollmentMarch 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Progressive Hemifacial Atrophy
Sponsor
R-Bio
Enrollment
5
Locations
1
Primary Endpoint
The volume change of fatty layer
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The purpose of this study is to investigate the efficacy and safety of autologous transplantation of adipose tissue derived mesenchymal stem cells (MSCs) in patient with progressive hemifacial atrophy.

Detailed Description

Adipose derived mesenchymal stem cells (AdMSCs) represent an attractive and ethical cell source for stem cell therapy. With the recent demonstration of MSC homing properties, intramuscular aplications of MSCs to cell-damaged diseases have increased. In a human clinical trial, five patients who had suffered a progressive hemifacial atrophy( Romberg's disease) were intramuscular administered autologous hAdMSCs (1×10e7 cells/500ul) with autologous microlipoinjection one time.

Registry
clinicaltrials.gov
Start Date
March 2008
End Date
February 2010
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
R-Bio
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects who understand and sign the consent form for this study.
  • Age :18-75, males and females.
  • Patients with symptom of hemifacial atrophy but not progress disease.

Exclusion Criteria

  • Patients with currently progressive hemifacial atrophy.
  • Women who are pregnant or breast feeding or planning to become pregnant during the study.
  • Subjects who don't understand purpose and method for this study.
  • Patients with psychical disorder or drug and alcohol addiction.
  • Participation in another clinical trial or treatment with a different investigational product within 30 days prior to inclusion in the study.
  • Serious pre-existing medical conditions like Cardiovascular Diseases, Renal Diseases, Liver Diseases, Endocrine Diseases, Cancer and Diabetes Mellitus.
  • Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria

Outcomes

Primary Outcomes

The volume change of fatty layer

Time Frame: 24 weeks

To evaluate the volume change of fatty layer using 3D camera.

Secondary Outcomes

  • Clinical lab tests(24 weeks)
  • Fat absorption rate(24 weeks)

Study Sites (1)

Loading locations...

Similar Trials